An 'Export-Only' Exception to Pharmaceutical Patents in Europe: Should the U.S. Follow Suit?
Nature Biotechnology, Vol. 37, No. 1, 03.01.2019, p. 21-22.
Posted: 24 Apr 2019
There are 2 versions of this paper
An 'Export-Only' Exception to Pharmaceutical Patents in Europe: Should the U.S. Follow Suit?
Nature Biotechnology, Vol.37, No. 1, pp. 21-22 (2019); DOI: 10.1038/nbt.4324
Posted: 27 Jun 2019
Date Written: March 26, 2019
Abstract
A new European Union policy could increase the supply of legitimate pharmaceuticals in developing countries and thereby minimize the problem of counterfeit medicines, but many challenges remain. This paper describes the proposed European legislation and discusses its' potential strengths, weaknesses, opportunities and threats. Ultimately, we consider if the United States should consider similar policies.
Suggested Citation: Suggested Citation
Minssen, Timo and Kesselheim, Aaron S. and Darrow, Jonathan J., An 'Export-Only' Exception to Pharmaceutical Patents in Europe: Should the U.S. Follow Suit? (March 26, 2019). Nature Biotechnology, Vol. 37, No. 1, 03.01.2019, p. 21-22., Available at SSRN: https://ssrn.com/abstract=3360308
Feedback
Feedback to SSRN
If you need immediate assistance, call 877-SSRNHelp (877 777 6435) in the United States, or +1 212 448 2500 outside of the United States, 8:30AM to 6:00PM U.S. Eastern, Monday - Friday.